Sarah Bos

60 CHAPTER 4 References 1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease : evidence and clinical consequences. Blood. 2010;116(6):878–85. 2. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56. 3. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol. 2013;163(5):666–73. 4. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - Possibilities and caveats. J Hepatol. 2013;59(2):358–66. 5. Investigators TH-V. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406–15. 6. Giugliano RP, Ruff CT, Braunwald E, Murphy, Sabina A, Wiviott, Stephen D, Halperin, Jonathan L, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. 7. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61(6):1721–7. 8. Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res. 2018;170(July):102–8. 9. Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60(1):425–6. 10. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395–405. 11. Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, et al. Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2019;8(5). 12. Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51–8. 13. PotzeW, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JCM, et al. Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. PLoS One. 2014 Feb;9(2):e88390. 14. PadriniR.Clinical PharmacokineticsandPharmacodynamicsofDirectOralAnticoagulants in Patients with Renal Failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1–12. 15. Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology. 2015 Apr;61(4):1435–6. 16. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel- group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa